# CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer

> **NCT03370159** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Wake Forest University Health Sciences**

## Conditions studied

- Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Stage IV Non-Small Cell Lung Cancer AJCC v7

## Interventions

- **DRUG:** 6,8-Bis(benzylthio)octanoic Acid
- **DRUG:** Docetaxel
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT03370159
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-06
- **Primary completion:** 2019-03-01
- **Final completion:** 2020-03-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decided not to move forward
- **Last updated:** 2018-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03370159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03370159, "CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03370159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*